Dyadic (DYAI) Highlights.
"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and animal health...
Adding Citius (CTXR) $0.55 to Watch List.
Best Presentation at Dawson James Conference.
We attended the Dawson James Conference on October 29th, which had over 20 medtech and biotech companies. The two...
Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.
Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.
Analyst Take: "Potential to be Revolutionary. Dyadic’s C1 shows potential in...
Investor Presentation Slides From Dyadic (DYA) $6.40.
Really, How Do We Do It?
Live Short Term Chart
INVESTOR PRESENTATION
LONGER TERM CHART
Client, see published reports for disclosure and disclaimer details.
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided...
Latest article
GeoVax (GOVX) Surges 256%, With 207 Million Shares Trading!
What an Entertaining Week!
..and it's only Thursday.
LIVE QUOTE
(MAY 18TH)
(MAY 21ST)
So Where Does That Leave us Today?
Yes, it was a pleasant surprise to see GeoVax...
Americore (AMCOF) Funding Launched. Looks Like Good Entry Point.
All Systems Go?
A recently completed Magnetometer survey sends a strong signal to investors that the company is advancing its project in a disciplined, data-driven...
Precious Metals Track Record
Updated 05/18/2026
Institutional Gold Analyst: 2026 Watch List.
*Past performace is no indication or even clue to future performance.
